Appili Buys Anti-Fungal Drug Rights

Appili Therapeutics Inc., the Halifax drug-discovery company that listed its shares in Toronto last spring, has acquired the rights to develop a new anti-fungal drug candidate from a Japanese drug company.
Appili issued a statement Thursday saying it has signed an agreement with Fujifilm Toyama Chemical Co. of Tokyo to develop an anti-fungal drug that can be used to fight such hard-to-cure